



2nd REGIONAL CONGRESS OF MEDICAL ONCOLOGY
Belgrade, Serbia, May 16-18th 2019

Guest Editors

Damir Vrbanec
Davorin Radosavljević
Jelena Spasić

Scientific Committee

Damir Vrbanec, president
Semir Bešlija
Jana Ocvirk
Stjepko Pleština
Siniša Radulović
Davorin Radosavljević
Vladimir Todorović

Local Organizing Committee

Davorin Radosavljević, president
Fedja Djordjević
Marijana Milović-Kovačević
Siniša Radulović
Marija Ristić
Jelena Spasić
Snežana Šušnjar



2nd REGIONAL CONGRESS OF MEDICAL ONCOLOGY Belgrade, Serbia, May 16-18th 2019

Dear colleagues and friends,

Regional collaboration of medical oncologists has been constantly improving during the last few years, especially in terms of a growing network of professional and personal contacts and their contribution to the success of recent joint meetings. This better networking is particularly of interest in the context of medical oncology as a young discipline and a widely accepted intention of unification of treatment standards in our clinical practice. The Association of Serbian Medical Oncologists (UMOS) with great pleasure and enthusiasm accepted to organize the Second Regional Congress of Medical Oncology (REKONIO) in Belgrade this May.

Medical oncology has always been a very dynamic field of research, and today we can strongly witness the outstanding progress in molecular diagnostics and treatment, having in hand two more powerful arms – molecularly targeted agents and immunotherapy with checkpoint inhibitors. Thus, the organisers of REKONIO decided to emphasise these advantages in therapy, to present the most important results in systemic treatment of solid tumors in three main sessions – cytotoxic chemotherapy, molecularly targeted and immunotherapy. Each of these „state-of-the art“ sessions will be followed by a separate case report session dedicated to the respective class of drugs, with enough time for discussion.

Around fifty abstracts from various field of medical oncology have been gathered in this Supplement, as a contribution of mainly younger oncologists to our Congress. Also, invited speakers contributed with extended abstracts of their talks. Thus, the content of this Supplement gives us a realistic picture of our local practices, drug availability and clinical research. The poster session will accordingly enlight those aspects, and award the best posters.

Enjoy REKONIO, Congress of regional understanding and cooperation!

Congress Chairs

Davorin Radosavljević

Siniša Radulović



2nd REGIONAL CONGRESS OF ONCOLOGICAL PHARMACY
Belgrade, Serbia, May 16-18th 2019.

Scientific Committee

Mirjana Antunović
Vesna Pavlica
Damir Vrbanec
Nataša Jovanović Lješević
Katarina Vučićević
Marko Skelin

Local Organizing Committee

Mirjana Bošković
Ivana Popović



2nd REGIONAL CONGRESS OF ONCOLOGICAL PHARMACY Belgrade, Serbia, May 16-18th 2019

The Congress will discuss and present the leading topics from oncology pharmacy as the youngest branch of pharmacy that includes comprehensive pharmaceutical care for oncology patients through rational and optimal use of oncological drugs and supportive therapies. The activities of a hospital oncology pharmacist are complementary with activities of other health workers in the oncology field. Include participation pharmacist in: a multiprofessional health team targeted at the area oncology, oncology pharmacy practices that include safe handling antineoplastic drugs and immunotherapy, as well as, complete pharmaceutical care for oncological patient.

The professional work of the congress through nine sessions and three workshops will be about the coverage of the different themes: safe handling of antineoplastic drugs, new drugs in treating solid tumors, pharmacovigilance, digital pharmacy in oncology, education in the area oncology pharmacies, oral antineoplastic drugs, suportative therapy, pharmaceutical supply and care of the oncological patient and case reports from daily practices as well as themed workshops. The work of the Congress will take the lead experts in the field of oncological pharmaceutical care from all countries of the region. The main goal of this Congress is the strengthening and positioning of Oncology pharmacy as a profession and strengthening regional cooperation in the field of oncology pharmacy in hospital and public pharmaceutical activities in order to better care for the oncologic patient.

We believe that this meeting is an opportunity to exchange the best possible way experiences, practices and problems in everyday work.

At the same time, the 2nd Regional Congress Of Internist Oncology is being held and in particular we look forward to mutual cooperation and exchange of information that is necessary as part of joint multiprofessional team treatment of oncological patients.

REFERENCES:

1. Quality Standard for the Oncology Service, German Society of Oncology Phatmacy for Europiean Society of Oncology Pharmacy, Safe handling cytotoxic drugs: Quapos 6, ESOP 2018.
2. Zhang S, Liao R, Alpert j. S, Kong J, Spetzger U, Milia P, Thiriet M, Wortley D. J. Digital medicine: Emergence, definition, scope, and future. Digital medicine. 2018. Vol. 4. (1).
- 3, Immunotherapy - new challenges in the treatment of oncological patients Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015; 125 (9): 3335-3337
4. Digital pharmacy Siska MH, Tribble YES. Opportunities and challenges related to technology in supporting optimal pharmacy practice models in hospitals and health systems. Am J Health Syst Pharm., 68 (12): 1116-1126. doi: 10.2146 / ajhp110059
5. Supportive therapy Kim JY, Wie GA, Cho YA et al. Development and validation of a screening tool for hospitalized cancer patients. Clin Nutr. 2011; 30 (6): 724-729. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27 (34): 5838-5847.